Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027

Passage BIO, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.
Company expects the cash position to fund operating expenses and capital expenditures into the first quarter of 2027.
Amount is preliminary, subject to completion of year-end financial review, adjustments, and audit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.